

**COLONY STIMULATING FACTORS  
PRIOR AUTHORIZATION FORM**  
(form effective 1/5/2026)



**Keystone First**

**PERFORMRx**<sup>SM</sup>  
Next Generation Pharmacy Benefits

Fax to PerformRx<sup>SM</sup> at **1-866-497-1387**, or to speak to a representative call **1-800-588-6767**.

PRIOR AUTHORIZATION REQUEST INFORMATION			
<input type="checkbox"/> New request <input type="checkbox"/> Renewal request		Total # of pages:	
Name of office contact:		Contact's phone number:	LTC facility contact/phone:
PATIENT INFORMATION			
Patient name:		Patient ID #:	DOB:
Street address:			
Apt #:	City/state/zip:		Phone:
PRESCRIBER INFORMATION			
Prescriber name:			
Specialty:		NPI:	State license #:
Street address:			
Suite #:	City/state/zip:		
Phone:		Fax:	
CLINICAL INFORMATION			
Medication requested:			
Preferred:		Non-Preferred:	
<input type="checkbox"/> Fulphila (pegfilgrastim-jmdb) Syringe <input type="checkbox"/> Fylnetra (pegfilgrastim-pbbk) Syringe <input type="checkbox"/> Granix (tbo-filgrastim) Syringe <input type="checkbox"/> Granix (tbo-filgrastim) Vial <input type="checkbox"/> Neupogen (filgrastim) Syringe <input type="checkbox"/> Neupogen (filgrastim) Vial <input type="checkbox"/> Releuko (filgrastim-ayow) Syringe <input type="checkbox"/> Releuko (filgrastim-ayow) Vial		<input type="checkbox"/> Leukine (sargramostim) Vial <input type="checkbox"/> Neulasta (pegfilgrastim) Onpro <input type="checkbox"/> Neulasta (pegfilgrastim) Syringe <input type="checkbox"/> Nivestym (filgrastim-aafi) Syringe <input type="checkbox"/> Nivestym (filgrastim-aafi) Vial <input type="checkbox"/> Nyvepria (pegfilgrastim-apgf) Syringe <input type="checkbox"/> Rolvedon (eflapegrastim-xnst) Syringe <input type="checkbox"/> Stimufend (pegfilgrastim-fpgk) Syringe <input type="checkbox"/> Udenyca (pegfilgrastim-cbvq) Autoinjector <input type="checkbox"/> Udenyca (pegfilgrastim-cbvq) Onbody <input type="checkbox"/> Udenyca (pegfilgrastim-cbvq) Syringe <input type="checkbox"/> Zarxio (filgrastim-sndz) Syringe <input type="checkbox"/> Ziextenzo (pegfilgrastim-bmez) Syringe	
Dosage form (e.g., vial, syringe, kit, etc.):			Strength:
Dose/route/frequency:		Quantity:	Refills:
Diagnosis ( <i>submit documentation</i> ):			Dx code ( <i>required</i> ):
Beneficiary's height:	in. / cm	Beneficiary's weight:	lbs / kg      BSA (Leukine only):      m <sup>2</sup>

**INITIAL REQUESTS**

Complete all sections that apply to the beneficiary and this request.  
Check all that apply and submit documentation for each item.

- Has recent results of a CBC with differential (submit copy of results)
- Is or will be receiving chemotherapy.  
List chemotherapy regimen: \_\_\_\_\_
- Is or will be receiving radiation therapy:  
Dates or planned dates of radiation: \_\_\_\_\_

**1. For a NON-PREFERRED Colony Stimulating Factor (CSF):**

- Has a history of trial and failure of or a contraindication or an intolerance to the preferred Colony Stimulating Factors that are approved or medically accepted for treatment of the beneficiary's diagnosis (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred drugs in this class.)  
List medications tried: \_\_\_\_\_

**2. Prophylaxis of chemotherapy-induced febrile neutropenia:**

- Has at least 1 of the following risk factors for the development of febrile neutropenia:
  - Age >65 years
  - Recent surgery
  - History of febrile neutropenia
  - Poor liver or kidney function
  - Current infection or open wound
  - Previous chemotherapy or radiation
  - Cardiovascular disease
  - Poor nutritional or performance status
  - other: \_\_\_\_\_
- Receiving or will receive a chemotherapy regimen with an expected incidence of neutropenia >20%
- For pegfilgrastim (Neulasta, Udenyca, etc.):  
Last date of chemo: \_\_\_\_\_ Planned administration date: \_\_\_\_\_ Next expected chemo date: \_\_\_\_\_

**3. Treatment of febrile neutropenia:**

- Received or is receiving myelosuppressive anticancer drugs associated with neutropenia
- Is at high risk for infection-related complications

**4. Bone marrow transplant:**

- Has a non-myeloid malignancy and is undergoing myeloablative chemotherapy to be followed by bone marrow transplant  
Planned transplant date: \_\_\_\_\_
- Has non-Hodgkin's lymphoma, acute lymphoblastic leukemia, or Hodgkin's lymphoma and had an autologous bone marrow transplant  
Transplant date: \_\_\_\_\_

**5. Stem cell transplant:**

- Is planned for autologous peripheral stem cell transplant
- Is planned for allogeneic peripheral stem cell transplant
- Will be using the requested medication in combination with plerixafor (also complete Mozobil prior authorization form) or another stem cell mobilizer  
Planned leukapheresis date: \_\_\_\_\_  
Planned transplant date: \_\_\_\_\_
- Had an autologous or allogeneic peripheral stem cell transplant  
Transplant date: \_\_\_\_\_

**6. Acute myeloid leukemia:**

- CSF will be used following induction chemotherapy
- CSF will be used following consolidation chemotherapy
- other: \_\_\_\_\_

**7. Hematopoietic syndrome of acute radiation syndrome:**

- Suspected or confirmed exposure to a radiation dose >2 gray (Gy)

**8. Severe chronic neutropenia — specify type:**     congenital neutropenia     cyclic neutropenia     idiopathic neutropenia

- Experiencing symptoms of neutropenia

**PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION**

Prescriber signature: _____	Date: _____
-----------------------------	-------------

**Confidentiality Notice:** The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or taking of any telecopy is strictly prohibited.